Day: July 21, 2025

Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland – July 21, 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents...

EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering. This follows the Company’s June 27, 2025 announcement of the agreements to cancel the remaining Series A Warrants, 59.5 million as at June 26, 2025, in exchange for a payment of $3.6 million. This initiative fully eliminates all overhanging rights from the registered direct offering in May 2025. For additional details, refer to the Company’s Form 6-K filed with the SEC on June 27, 2025. About NuCana NuCana...

Earnings Webcast and Conference Call Set for Tuesday, July 29, 2025 at 5:00 p.m. ET Miami, FL, July 21, 2025 (GLOBE NEWSWIRE) — MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital energy and infrastructure company, will hold a webcast and conference call on Tuesday, July 29, 2025 at 5:00 p.m. Eastern time to discuss its financial results for the quarter ended June 30, 2025. Financial results will be published in a shareholder letter prior to the call on the investor relations section of the Company’s website. To register to participate in the conference call or to listen to the live audio webcast, please use this link. The webcast will also be broadcast live and available for replay via the investor relations section of the Company’s website. Verified retail and institutional...

GUANGZHOU, China, July 21, 2025 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD), a global leader in autonomous driving technology, today launched the HPC 3.0 high-performance computing platform, jointly developed with Lenovo (HKSE: 0992) and powered by NVIDIA’s (NASDAQ: NVDA) latest DRIVE AGX Thor chips. The new HPC 3.0 platform makes its debut in WeRide’s latest-generation Robotaxi GXR — making it the world’s first mass-produced Level 4 (L4) autonomous vehicle built on NVIDIA DRIVE AGX Thor. Fully automotive-grade, HPC 3.0 reduces autonomous driving suite cost by 50%, paving the way for GXR’s large-scale commercial deployment. WeRide’s HPC 3.0 platform, featuring a dual NVIDIA DRIVE AGX Thor configuration running the safety-certified DriveOS, is built on Lenovo’s AD1 L4 autonomous driving domain controller...

CALGARY, Alberta, July 21, 2025 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) (“CEMATRIX” or the “Company“), a specialty construction contractor that produces cellular concrete solutions on site and is a leading manufacturer and supplier of cellular concrete in North America announced today that it has won $5.1 million in new contract awards.   New Contract Award Details:a load reducing fill application on a highway improvement project; a load reducing fill application for a tank base project; a load reducing fill application for a void fill project; the remaining projects are all small to mid-sized projects for lightweight fill applications in Canada and the US.“These new awards continue to demonstrate the confidence that our customers have in CEMATRIX’s sales and operations teams...

WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a mid-year Shareholder Letter to update investors on recent corporate developments and to highlight near-term value-building R&D milestones for second half of 2025. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Shareholders: Over my 40-year career, I’ve seen the full arc of biotech—celebrated successes and weathered setbacks. Today’s biotech environment ranks among the most challenging we’ve faced: capital...

BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans (the “new term B loans”) under a new term loan facility (the “Term Loan Facility”). The Issuer has also launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the “notes”) in a private offering. The Issuer intends to use the net proceeds of the new term B loans and the notes to refinance its existing term B loans in full, to repay a portion of outstanding amounts borrowed under its ABL facility and to pay related fees, premiums and expenses. The offering of the notes is not conditioned on entry into the Term Loan Facility. The...

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to dateCAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the company’s pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline. In the next few years,...

Vancouver, British Columbia, July 21, 2025 (GLOBE NEWSWIRE) — First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (the “Company”) announces that the Company intends to consolidate the common shares in the capital of the Company (the “Shares”) on the basis of one (1) post-consolidated Share for each two (2) pre-consolidated Shares (the “Consolidation”). The Company currently has 12,247,181 Shares issued and outstanding on a pre-consolidation basis. If the proposed Consolidation is undertaken, then the Company will have approximately 6,123,590 Shares, subject to rounding, issued and outstanding on a post-consolidation basis. No fractional shares will be issued as a result of the Consolidation. Any fractional shares resulting from the Consolidation will be rounded up or down to the nearest whole Share. The Company’s outstanding...